Russian developers of Sputnik V plan to produce 850 mn doses a year in India

0
117
The Russian developers of the Sputnik V Covid-19 vaccine, which has been granted approval by India’s drug controller for emergency use, have tied up with several Indian pharmaceutical firms to manufacture more than 850 million doses a year.
The developers – Gamaleya National Research Center for Epidemiology and Microbiology named and Russian Direct Investment Fund (RDIF) – initially tied up with Dr Reddy’s Laboratories for trials, regulatory approvals and distribution of the vaccine.
Dr Reddy’s has the rights for distribution of the first 100 million doses in India, which will be a combination of Indian and Russian made vaccines. Since March, the developers have stitched up more agreements to ramp up the production of the vaccine in India.
This includes agreements with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech aimed at the production of more than 850 million doses a y

RELATED ARTICLESMORE FROM AUTHOR